Roche Sequencing Solutions, Inc.

Roche Sequencing Solutions, Inc. has been granted 273 US utility patents between 2017 and 2025, placing Roche Sequencing Solutions, Inc. at rank #1,528 across all assignees tracked by PlainPatent. This portfolio spans 40 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.1 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Roche Sequencing Solutions, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 59.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 254 grants, compared with 19 in the 2015–2019 window — a +1237% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Roche Sequencing Solutions, Inc.'s 15.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 40 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Roche Sequencing Solutions, Inc. against peers pursuing similar technology classes.